Our team

Lorenz has over 30 years’ experience in biopharma research, development and commercialization. Most recently, he was Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for research investments, talent development and company growth strategy across all business areas. His former positions include Vice President & Global Head at AstraZeneca, where he oversaw the generation of biological reagents and assay development activities across all therapeutic areas, and Executive Director at Novartis.

Lorenz is a biochemistry lecturer at the Martin Luther University Halle-Wittenberg and has published over 60 peer-reviewed papers.

Tom has over 25 years’ diverse and rich experience in biopharma. His industry experience comprises time spent as CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio after a long career at Johnson & Johnson, which includes four years as worldwide Vice President of Finance and CFO of Ethicon. Most recently, he has been appointed CEO-CFO of Oxurion (EBR: OXUR), a clinical-stage biopharmaceutical company developing next-generation ophthalmic therapies. To date, he has contributed towards the raising of more than $500 Million USD on both private and public capital markets. A Chartered Financial Analyst, Certified Financial Manager and Management Accountant, Graney holds a BS in accounting from the University of Delaware and an MBA in Marketing, Finance and International Business from the Leonard N. Stern School of Business at New York University.

Joe began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner’s (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in molecular and cellular biology from the University of Bath and an MPhil in business management from the University of Cambridge.

Representing Parkwalk Advisors, which he co-founded in 2009, Alastair was a Partner of Lazard LLP, Director of BNP and a Founder Partner of Ark Securities. He has analyzed and advised both private and public companies on strategy, development, fund-raising and exits. He oversees the investment process at Parkwalk and he sits on various portfolio company Boards, including Congenica, PhoreMost, PredictImmune, Aqdot and Mirriad.

Joanna Green is a Principal at Ahren Innovation Capital.

Joanna joined Ahren from the Boston Consulting Group (BCG), where she worked on strategic projects across a range of industries including healthcare, insurance and the public sector.

Joanna holds a PhD in fetal immunology, focusing on childhood leukemia, and a First-Class Master’s and undergraduate degree from the University of Oxford.

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Tada joined Astellas Venture Management (AVM) in April 2018. Tada has been involved in multiple investments, including Mogrify as well as emerging technology companies in the field of in vivo cell engineering, cellar rejuvenation, full tooth regeneration etc. Prior to which he worked in Innovation Management at Astellas Pharma Inc. from 2016-2018, in charge of business transaction for early stage partnering deals. From 2009 – 2016, he worked for Clinical Pharmacology Department at Astellas Pharma Inc. taking a lead in preparing early-stage clinical development plans. He also led clinical study protocol preparation and data analysis, and coordinated and managed preparation of applications for Clinical Pharmacology components, including Briefing Documents, INDs and NDAs and represented as a Clinical Pharmacology representative to the relevant regulatory authorities. He started his career as a Research Scientist at MSD (Former Banyu Pharmaceutical co., LTD. a subsidiary of Merck & Co., Inc.) in April 2005 with background on pharmacokinetics and molecular biology.